Attached files
file | filename |
---|---|
EX-99.2 - China Botanic Pharmaceutical | v187843_ex99-2.htm |
EX-99.1 - China Botanic Pharmaceutical | v187843_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 7, 2010
RENHUANG
PHARMACEUTICALS, INC.
(Exact
name of Registrant as Specified in its Charter)
Nevada
|
0-24512
|
88-1273503
|
||
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
No.
281, Taiping Road, Taiping District
Harbin,
Heilongjiang Province, 150050
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: 86-451-5762-0378
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM 2.02. Results of Operations
and Financial Condition
On June
7, 2010, Renhuang Pharmaceuticals, Inc. (the “Company”) issued a press
release announcing the Company’s financial results for the second quarter ended
April 30, 2010. A copy of this press release is attached hereto as
Exhibit 99.1.
The
Company’s management team held a conference call on June 8, 2010 at 9:00 a.m.
Eastern Time to review the aforementioned financial results. A replay of the
conference call will be available from Tuesday June 8, 2010 at 10:00 a.m.
Eastern Time through Tuesday June 22, 2010. To access the replay,
dial 800-642-1687. International callers should dial +1
706-645-9291. The conference ID number for the call is
79282265. A copy of the conference call transcript is attached hereto
as Exhibit 99.2.
The
information in this Item 2.02 of Form 8-K, including the accompanying
exhibits, shall not be deemed to be “filed” for the purposes of Section 18
of the Securities and Exchange Act of 1934 (the “Exchange Act”), or otherwise
subject to the liability of such section, nor shall such information be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, regardless of the general incorporation language of such filing,
except as shall be expressly set forth by specific reference in such
filing.
In
accordance with the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, the Company notes that certain statements set forth in this
Current Report on Form 8-K provide other than historical information and are
forward looking. The actual achievement of any forecasted results, or the
unfolding of future economic or business developments in a way anticipated or
projected by the Company, involve numerous risks and uncertainties that may
cause the Company’s actual performance to be materially different from that
stated or implied in the forward-looking statement.
Item
7.01 Regulation FD Disclosure.
The
response to Item 2.02 is incorporated herein by reference to this
Item 7.01.
The
information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”) or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such filing.
In
accordance with the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, the Company notes that certain statements set forth in this
Current Report on Form 8-K provide other than historical information and are
forward looking. The actual achievement of any forecasted results, or the
unfolding of future economic or business developments in a way anticipated or
projected by the Company, involve numerous risks and uncertainties that may
cause the Company’s actual performance to be materially different from that
stated or implied in the forward-looking statement.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No.
|
Description
|
|
99.1*
|
Press
Release dated June 7, 2010 announcing second quarter 2010 financial
results
|
|
99.2*
|
Conference
Call Transcript dated June 8, 2010
|
*
|
Such
Exhibit is being “furnished” (not filed) pursuant to Item 2.02 and
Item 7.01 of the Current Report on Form
8-K.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
RENHUANG
PHARMACEUTICALS, INC.
|
||||
Date:
June 9, 2010
|
By:
|
/s/
Shaoming Li
|
||
Shaoming
Li
|
||||
Chief
Executive Officer
|
EXHIBIT
INDEX
Exhibit
|
||
Number
|
Description
|
|
99.1*
|
Press
Release dated June 7, 2010 announcing first quarter 2010 financial
results
|
|
99.2*
|
Conference
Call Transcript dated June 8, 2010
|
*
|
Such
Exhibit is being “furnished” (not filed) pursuant to Item 2.02 and
Item 7.01 of the Current Report on Form
8-K.
|